OTCMKTS:ADXS Ayala Pharmaceuticals - ADXS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.35 -0.15 (-10.00%) (As of 03/24/2023 08:52 PM ET) Add Compare Share Share Today's Range$1.30▼$1.4050-Day Range$1.30▼$1.8052-Week Range$1.00▼$10.71Volume1,000 shsAverage Volume7,684 shsMarket Capitalization$2.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort Interest About Ayala Pharmaceuticals (OTCMKTS:ADXS) StockAdvaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.Read More Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Stock News HeadlinesMarch 27, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Receives New Coverage from Analysts at StockNews.comMarch 26, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)March 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 23, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Ayala Pharmaceuticals (OTCMKTS:ADXS)March 21, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Research Coverage Started at StockNews.comMarch 18, 2023 | americanbankingnews.comAyala Pharmaceuticals (OTCMKTS:ADXS) Earns Sell Rating from Analysts at StockNews.comMarch 3, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring CommitteeFebruary 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022March 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.January 19, 2023 | finance.yahoo.comAdvaxis and Ayala Pharmaceuticals Complete MergerDecember 25, 2022 | finance.yahoo.comAdvaxis, Inc. (ADXS) Stock Historical Prices & Data - Yahoo FinanceOctober 20, 2022 | streetinsider.comForm 8-K Advaxis, Inc. For: Oct 18 - StreetInsider.comOctober 20, 2022 | finance.yahoo.comRedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate - Yahoo FinanceOctober 19, 2022 | benzinga.comWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session - - BenzingaOctober 19, 2022 | businesswire.comAYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders - Business WireOctober 19, 2022 | baystreet.caAyala, Advaxis Merge - Baystreet.caOctober 19, 2022 | marketwatch.comAyala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS - MarketWatchOctober 19, 2022 | finance.yahoo.comAyala Pharmaceuticals and Advaxis Enter into Merger Agreement - Yahoo FinanceOctober 19, 2022 | seekingalpha.comAyala stock rises 16% on all-stock merger with Advaxis to focus on cancer drugs - Seeking AlphaOctober 19, 2022 | globenewswire.comAdvaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswireOctober 17, 2022 | globenewswire.comRich Insights into the Metastatic Urothelial Carcinoma Clinical Trial Analysis Featuring 40+ Companies and Therapies | DelveInsight - GlobeNewswireOctober 13, 2022 | globenewswire.comHerbal Medicinal Products Market Is Expected to Grasp the Value of USD 177.65 Billion with Growing CAGR of 6.83% by 2029, Size, Shares, Trends, Growth and Revenue Outlook - GlobeNewswireOctober 4, 2022 | finance.yahoo.comBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - Yahoo FinanceOctober 4, 2022 | benzinga.comBlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer - BenzingaSeptember 28, 2022 | streetinsider.comReunion Neuroscience (REUN) Appoints Greg Mayes as President and CEO - StreetInsider.comSeptember 28, 2022 | finance.yahoo.comReunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive OfficerSeptember 28, 2022 | markets.businessinsider.comReunion Neuroscience Names Greg Mayes As President And CEOSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Company Calendar Last Earnings9/09/2021Today3/26/2023Next Earnings (Estimated)6/06/2023Fiscal Year End10/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ADXS CUSIPN/A CIK1100397 Webwww.advaxis.com Phone(609) 452-9813Fax609-452-9818Employees14Year Founded2002Profitability EPS (Most Recent Fiscal Year)($8.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,860,000.00 Net MarginsN/A Pretax Margin-6,064.80% Return on Equity-54.02% Return on Assets-47.27% Debt Debt-to-Equity RatioN/A Current Ratio15.64 Quick Ratio15.64 Sales & Book Value Annual Sales$3.24 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value$21.36 per share Price / Book0.06Miscellaneous Outstanding Shares1,816,000Free Float1,811,000Market Cap$2.45 million OptionableOptionable Beta2.44 Social Links Key ExecutivesKen BerlinPresident, Chief Executive Officer & DirectorIgor GitelmanVP-Finance, Chief Financial & Accounting OfficerAndres A. GutiérrezChief Medical Officer & Executive Vice PresidentMichael GraceVice President-Technical OperationsKey CompetitorsBellicum PharmaceuticalsNASDAQ:BLCMFirst Wave BioPharmaNASDAQ:FWBIVirios TherapeuticsNASDAQ:VIRIContraFectNASDAQ:CFRXWellness Center USAOTCMKTS:WCUIView All Competitors ADXS Stock - Frequently Asked Questions How have ADXS shares performed in 2023? Ayala Pharmaceuticals' stock was trading at $1.20 on January 1st, 2023. Since then, ADXS stock has increased by 12.5% and is now trading at $1.35. View the best growth stocks for 2023 here. When is Ayala Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 6th 2023. View our ADXS earnings forecast. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (OTCMKTS:ADXS) posted its quarterly earnings results on Thursday, September, 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The biotechnology company earned $0.25 million during the quarter. What is Ayala Pharmaceuticals' stock symbol? Ayala Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ADXS." How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ayala Pharmaceuticals' stock price today? One share of ADXS stock can currently be purchased for approximately $1.35. How much money does Ayala Pharmaceuticals make? Ayala Pharmaceuticals (OTCMKTS:ADXS) has a market capitalization of $2.45 million and generates $3.24 million in revenue each year. The biotechnology company earns $-17,860,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis. How can I contact Ayala Pharmaceuticals? Ayala Pharmaceuticals' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The official website for the company is www.advaxis.com. The biotechnology company can be reached via phone at (609) 452-9813, via email at ir@advaxis.com, or via fax at 609-452-9818. This page (OTCMKTS:ADXS) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.